Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2025 financial results on May 1, 2025. Lilly will also conduct a conference call that day with the investment community and media ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes. By Rebecca Robbins and Gina Kolata Encouraging ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...

Ore Huiying / Bloomberg / Getty Images Shares of Eli Lilly jumped 16% Thursday morning after the pharmaceutical company released Phase 3 trial results for its oral weight-loss drug that ...

Art has always found nature to be one of its greatest sources of inspiration, and the four elements – Earth, Air, Fire, and Water – have been represented throughout the centuries with profound ...

Tom Brady's playful rivalry with Eli Manning reignited after a viral video showed Brady joking about never losing to Manning, referencing their Super Bowl clashes. Giants fans swiftly responded ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results from a candidate that could be a game changer in this area of high demand ...

Orforglipron, an experimental treatment Eli Lilly is developing for diabetes and weight loss, hit high marks in the first of several pivotal trials. The daily tablet produced blood-sugar ...

Eli Lilly shares jumped 15% after a clinical trial of its experimental pill showed it helped patients with Type 2 diabetes lose weight at levels comparable to leading injectable medications like ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of ...

25.7 x 25.1 cm. (10.1 x 9.9 in.) ...